1832 Asset Management’s NovoCure NVCR Stock Holding History

1832 Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-39,800	Closed	-$8.89M	–	872
2021 Q2	$8.89M	Buy	+39,800	New	+$7.74M	0.02%	327

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

1832 Asset Management's NVCR Position: Q3 2021 in Review

1832 Asset Management sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 39,800 shares — an estimated $8.89M sold.

1832 Asset Management first reported a position in NVCR in Q2 2021 and held it in 1 quarter. The position peaked at $8.89M in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

1832 Asset Management reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
1832 Asset Management sold 39,800 NovoCure shares in Q3 2021, an estimated $8.89M.
1832 Asset Management first reported a position in NovoCure in Q2 2021 and held it in 1 quarter.
1832 Asset Management's NovoCure position peaked at $8.89M in Q2 2021.
317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on 1832 Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.